Our study suggests that the presence of KRAS mutations in advanced NSCLC patients has a poor prognostic value, regardless of their PDL1 expression values, after receiving immunotherapy as first-line treatment. This evidence concerns the gene KRAS and non-small cell lung carcinoma.